Mannella Email Address

Veloxis Pharmaceuticals (LCP) is an emerging specialty pharmaceutical company, focused on certain cardiovascular indications and organ transplantation in particular. The intention is to approach the transplantation market through our own, hospital-based specialist sales force and to use marketing and sales partners for the cardiovascular indications. We believe that our proprietary MeltDose(r) technology platform enables us to develop drugs which achieve the same efficacy as currently commercialized drugs, but at lower doses. The results are generally better bioavailability, a reduction in potential interaction with food and other drugs, and in some cases, reduced side effects.